A method for single-cell DNA analysis could provide a safer genetic screen for IVF.
Computer-controlled sedation could lighten the load for intensive-care staff and make the process safer for patients.
Dimension Therapeutics wants to develop a lifetime fix for hemophilia using gene therapy.
The way DNA strands contract when they come into contact with viruses could lead to cheap and simple pathogen detectors, say physicists.
A startup will sift through “treasure troves” of data from failed trials to find abandoned Alzheimer’s drugs that might work for some patients.
The U.K. plans to sequence 100,000 National Health Service patients by 2017—in a bold push to be a genomic medicine leader.
Spark Therapeutics hopes to commercialize multiple gene-based treatments developed at the Children's Hospital of Philadelphia.
The newest cancer drugs cost over $100,000 for a year of treatment. There are fairer ways to set prices.
Today’s medicines can cost hundreds of thousands of dollars a year. The story of how two companies set prices for their costly new drugs suggests that the way we determine the value of such treatments will help decide the future of our health-care system.
Biotech startup Greenlight Biosciences has a cell-free approach to microbial chemical production.